SCHEMBL23975978

SCHEMBL23975978

OCc1nncn1-c1cccc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.49
KMT2A Q03164 1/20 0.43
KEAP1 Q14145 1/20 0.41
PI4KA P42356 1/20 0.40
PI4K2B Q8TCG2 1/20 0.40
PI4K2A Q9BTU6 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
LGALS3 P17931 1/20 0.39
OPRD1 P41143 3/20 0.38
DHODH Q02127 5/20 0.37
OPRM1 P35372 1/20 0.37
MAPK1 P28482 1/20 0.37
FAAH O00519 1/20 0.37
MGLL Q99685 1/20 0.37
GRM1 Q13255 1/20 0.36
RXRA P19793 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23975979 0.84 KMT2A (0.43) NOTUMKMT2AKEAP1PI4KAPI4K2B
SCHEMBL30225176 0.84 KMT2A (0.43) NOTUMKMT2AKEAP1PI4KAPI4K2B
SCHEMBL30431316 0.81 NOTUM (0.49) NOTUMLGALS3OPRD1MAPK1MGLL
SCHEMBL23975970 0.81 MAPK1 (0.43) NOTUMKMT2AKEAP1PI4KAPI4K2B
SCHEMBL23975974 0.81 KMT2A (0.40) NOTUMKMT2AKEAP1PI4KAPI4K2B
SCHEMBL29089722 0.80 MAPK1 (0.53) NOTUMKMT2AOPRD1OPRM1MAPK1
SCHEMBL10719067 0.76 KMT2A (0.46) NOTUMKMT2AKEAP1PI4KAPI4K2B
SCHEMBL22290182 0.71 NOTUM (0.45) NOTUMKMT2AKEAP1PI4KAPI4K2B
SCHEMBL9663546 0.70 TP53 (0.51) NOTUMPI4KAPI4K2BPI4K2API4KB
SCHEMBL3060399 0.69 NOTUM (0.46) NOTUMKEAP1PI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
EP-4142732-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS Global Blood Therapeutics, Inc. (US) 2023-03-08 EP disclosed
EP-4143178-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS Global Blood Therapeutics, Inc. (US) 2023-03-08 EP disclosed
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2022-12-15 US disclosed
WO-2021222483-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 NOTUM 4249/4885KMT2A 4375/4885KEAP1 135/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI NOTUM 4393/4885KMT2A 4677/4885KEAP1 45/4885
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI NOTUM 4393/4885KMT2A 4677/4885KEAP1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.